Home›Salicylates

Salicylates

55 interactions on record

Salicylates has 55 known drug interactions based on U.S. FDA drug labeling data. 14 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Dorzolamide Hydrochloride, Enoxaparin Sodium, Furosemide. Patients taking Salicylates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 55
Major: 14
Moderate: 41

Major (14)

Salicylates + Dorzolamide Hydrochloride— High-dose salicylate therapy may result in acid-base and electrolyte disturbances and associated toxicity when combined …
Salicylates + Enoxaparin Sodium— May enhance risk of hemorrhage. Discontinue prior to Lovenox initiation if possible, or conduct close clinical and labor…
Salicylates + Furosemide— High-dose salicylates with furosemide may cause salicylate toxicity at lower doses due to competitive renal excretion.
Salicylates + Furosemide, Benzalkonium Chloride— Patients receiving high doses of salicylates concomitantly with furosemide may experience salicylate toxicity at lower d…
Salicylates + Glyburide And Metformin Hydrochloride— Salicylates may potentiate the hypoglycemic action of glyburide. Close observation for hypoglycemia required.
Salicylates + Insulin Degludec— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Salicylates + Insulin Glargine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Salicylates + Insulin Glargine-Yfgn— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Salicylates + Methotrexate— Caution should be used when salicylates are administered concomitantly with methotrexate. These drugs reduce tubular sec…
Salicylates + Methotrexate Sodium— Salicylates may increase methotrexate plasma concentrations and are weak acids that increase methotrexate exposure.
Salicylates + Potassium Phosphate, Monobasic And Sodium Phosphate, Monobasic, Anhydrous— Administration of monobasic phosphates may lead to toxic salicylate levels due to decreased excretion in acidified urine…
Salicylates + Prednisolone Sodium Phosphate— Concomitant use increases gastrointestinal side effects; clearance of salicylates may be increased.
Salicylates + Torsemide— Compete for renal tubular secretion; high-dose salicylates may experience salicylate toxicity when given with torsemide.
Salicylates + Triamcinolone Acetonide— Concomitant use with corticosteroids increases risk of gastrointestinal side effects. Clearance of salicylates may be in…

Moderate (41)

Salicylates + Betamethasone Sodium Phosphate, Betamethasone Acetate, Lidocaine, Iodixanol, Povidine Iodine— Clearance of salicylates may be increased with concurrent corticosteroid use.
Salicylates + Bromocriptine Mesylate— Bromocriptine may increase the unbound fraction of highly protein-bound salicylates, potentially altering their effectiv…
Salicylates + Depo-Medrol, Lidocaine, Isopropyl Alcohol— Clearance of salicylates may be increased by corticosteroids.
Salicylates + Dorzolamide Hydrochloride And Timolol Maleate Ophthalmic Solution— High-dose salicylate therapy may cause acid-base and electrolyte disturbances and associated toxicity when combined with…
Salicylates + Dorzolamide Hydrochloride And Timolol Maleate Preservative Free— Potential for acid-base and electrolyte disturbances and toxicity with high-dose salicylate therapy.
Salicylates + Fosphenytoin Sodium— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Salicylates + Furosemide Injection 80 Mg/ 10 Ml— May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of …
Salicylates + Glibenclamide— May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.
Salicylates + Glimepiride— Highly protein-bound drugs that may increase glucose-lowering effect of glimepiride, increasing susceptibility to hypogl…
Salicylates + Glipizide— Salicylates may potentiate hypoglycemic action of glipizide. Caution should be exercised; in vitro studies suggest glipi…
Salicylates + Glipizide And Metformin Hydrochloride— Salicylates may potentiate the hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia.
Salicylates + Glyburide-Metformin Hydrochloride— May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.
Salicylates + Griseofulvin— Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly.
Salicylates + Hyaluronidase— Large doses of salicylates may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs ren…
Salicylates + Hyaluronidase, Ovine— Large doses may require larger amounts of hyaluronidase for equivalent dispersing effect; tissues become partly resistan…
Salicylates + Insulin Aspart Injection— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Salicylates + Insulin Aspart-Szjj— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Salicylates + Insulin Degludec And Liraglutide— May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.
Salicylates + Insulin Detemir— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Salicylates + Insulin Glargine And Lixisenatide— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Salicylates + Insulin Glargine-Aglr— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Salicylates + Insulin Glulisine— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Salicylates + Insulin Human— May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
Salicylates + Insulin Lispro— May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
Salicylates + Insulin Lispro-Aabc— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
Salicylates + Ketorolac Tromethamine— At therapeutic concentrations, salicylate reduces ketorolac protein binding from 99.2% to 97.5%, representing potential …
Salicylates + Levothyroxine Sodium— At doses >2 g/day, inhibit binding of T4 and T3 to TBG and transthyretin, initially increasing FT4 followed by return to…
Salicylates + Liothyronine Sodium— At doses >2 g/day, salicylates inhibit binding of T4 and T3 to TBG and transthyretin, with initial increase in serum FT4…
Salicylates + Methenamine Mandelate— Concurrent use may lead to increased serum salicylate levels due to reduced excretion in acidified urine.
Salicylates + Metolazone— May decrease the antihypertensive effects of metolazone.
Salicylates + Nateglinide— May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increa…
Salicylates + Phenytoin— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Salicylates + Phenytoin Sodium— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Salicylates + Potassium Phosphate, Monobasic— May increase serum salicylate levels due to reduced excretion in acidified urine. Serum levels should be closely monitor…
Salicylates + Pramlintide Acetate— May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution.
Salicylates + Prednisone— Concomitant use increases risk of gastrointestinal side effects.
Salicylates + Probenecid— Salicylates antagonize the uricosuric action of probenecid.
Salicylates + Probenecid And Colchicine— Salicylates antagonize the uricosuric action of probenecid.
Salicylates + Sodium Chloride, Sodium Lactate, Potassium Chloride, Calcium Chloride And Dextrose Monohydrate— Renal clearance of acidic drugs like salicylates may be increased due to alkalinizing action of lactate.
Salicylates + Sulfadiazine— Salicylates may displace sulfonamides from plasma albumin and increase concentrations of free drug in plasma.
Salicylates + Timolol Maleate— High-dose salicylate therapy may cause acid-base and electrolyte disturbances leading to toxicity when combined with dor…

Salicylates + Dorzolamide Hydrochloride⚠️Major

High-dose salicylate therapy may result in acid-base and electrolyte disturbances and associated toxicity when combined with dorzolamide.

Salicylates + Enoxaparin Sodium⚠️Major

May enhance risk of hemorrhage. Discontinue prior to Lovenox initiation if possible, or conduct close clinical and laboratory monitoring if coadministration is essential.

Salicylates + Furosemide⚠️Major

High-dose salicylates with furosemide may cause salicylate toxicity at lower doses due to competitive renal excretion.

Salicylates + Furosemide, Benzalkonium Chloride⚠️Major

Patients receiving high doses of salicylates concomitantly with furosemide may experience salicylate toxicity at lower doses due to competitive renal excretory sites.

Salicylates + Glyburide And Metformin Hydrochloride⚠️Major

Salicylates may potentiate the hypoglycemic action of glyburide. Close observation for hypoglycemia required.

Salicylates + Insulin Degludec⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Salicylates + Insulin Glargine⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Salicylates + Insulin Glargine-Yfgn⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Salicylates + Methotrexate⚠️Major

Caution should be used when salicylates are administered concomitantly with methotrexate. These drugs reduce tubular secretion of methotrexate and may displace it from serum albumin binding, enhancing toxicity.

Salicylates + Methotrexate Sodium⚠️Major

Salicylates may increase methotrexate plasma concentrations and are weak acids that increase methotrexate exposure.

Salicylates + Potassium Phosphate, Monobasic And Sodium Phosphate, Monobasic, Anhydrous⚠️Major

Administration of monobasic phosphates may lead to toxic salicylate levels due to decreased excretion in acidified urine.

Salicylates + Prednisolone Sodium Phosphate⚠️Major

Concomitant use increases gastrointestinal side effects; clearance of salicylates may be increased.

Salicylates + Torsemide⚠️Major

Compete for renal tubular secretion; high-dose salicylates may experience salicylate toxicity when given with torsemide.

Salicylates + Triamcinolone Acetonide⚠️Major

Concomitant use with corticosteroids increases risk of gastrointestinal side effects. Clearance of salicylates may be increased.

Salicylates + Betamethasone Sodium Phosphate, Betamethasone Acetate, Lidocaine, Iodixanol, Povidine Iodine🟡Moderate

Clearance of salicylates may be increased with concurrent corticosteroid use.

Salicylates + Bromocriptine Mesylate🟡Moderate

Bromocriptine may increase the unbound fraction of highly protein-bound salicylates, potentially altering their effectiveness and risk for side effects.

Salicylates + Depo-Medrol, Lidocaine, Isopropyl Alcohol🟡Moderate

Clearance of salicylates may be increased by corticosteroids.

Salicylates + Dorzolamide Hydrochloride And Timolol Maleate Ophthalmic Solution🟡Moderate

High-dose salicylate therapy may cause acid-base and electrolyte disturbances and associated toxicity when combined with dorzolamide.

Salicylates + Dorzolamide Hydrochloride And Timolol Maleate Preservative Free🟡Moderate

Potential for acid-base and electrolyte disturbances and toxicity with high-dose salicylate therapy.

Salicylates + Fosphenytoin Sodium🟡Moderate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Salicylates + Furosemide Injection 80 Mg/ 10 Ml🟡Moderate

May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of salicylate toxicity.

Salicylates + Glibenclamide🟡Moderate

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

Salicylates + Glimepiride🟡Moderate

Highly protein-bound drugs that may increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

Salicylates + Glipizide🟡Moderate

Salicylates may potentiate hypoglycemic action of glipizide. Caution should be exercised; in vitro studies suggest glipizide does not interact with salicylate but clinical extrapolation warranted.

Salicylates + Glipizide And Metformin Hydrochloride🟡Moderate

Salicylates may potentiate the hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia.

Salicylates + Glyburide-Metformin Hydrochloride🟡Moderate

May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.

Salicylates + Griseofulvin🟡Moderate

Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly.

Salicylates + Hyaluronidase🟡Moderate

Large doses of salicylates may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs render tissues partly resistant to hyaluronidase action.

Salicylates + Hyaluronidase, Ovine🟡Moderate

Large doses may require larger amounts of hyaluronidase for equivalent dispersing effect; tissues become partly resistant to hyaluronidase action.

Salicylates + Insulin Aspart Injection🟡Moderate

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Salicylates + Insulin Aspart-Szjj🟡Moderate

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Salicylates + Insulin Degludec And Liraglutide🟡Moderate

May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

Salicylates + Insulin Detemir🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Salicylates + Insulin Glargine And Lixisenatide🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Salicylates + Insulin Glargine-Aglr🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Salicylates + Insulin Glulisine🟡Moderate

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Salicylates + Insulin Human🟡Moderate

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

Salicylates + Insulin Lispro🟡Moderate

May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.

Salicylates + Insulin Lispro-Aabc🟡Moderate

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Salicylates + Ketorolac Tromethamine🟡Moderate

At therapeutic concentrations, salicylate reduces ketorolac protein binding from 99.2% to 97.5%, representing potential two-fold increase in unbound ketorolac plasma levels.

Salicylates + Levothyroxine Sodium🟡Moderate

At doses >2 g/day, inhibit binding of T4 and T3 to TBG and transthyretin, initially increasing FT4 followed by return to normal with possible 30% decrease in total T4.

Salicylates + Liothyronine Sodium🟡Moderate

At doses >2 g/day, salicylates inhibit binding of T4 and T3 to TBG and transthyretin, with initial increase in serum FT4 followed by normalization. Total T4 levels may decrease by up to 30%. Closely monitor thyroid parameters.

Salicylates + Methenamine Mandelate🟡Moderate

Concurrent use may lead to increased serum salicylate levels due to reduced excretion in acidified urine.

Salicylates + Metolazone🟡Moderate

May decrease the antihypertensive effects of metolazone.

Salicylates + Nateglinide🟡Moderate

May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Salicylates + Phenytoin🟡Moderate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Salicylates + Phenytoin Sodium🟡Moderate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Salicylates + Potassium Phosphate, Monobasic🟡Moderate

May increase serum salicylate levels due to reduced excretion in acidified urine. Serum levels should be closely monitored.

Salicylates + Pramlintide Acetate🟡Moderate

May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution.

Salicylates + Prednisone🟡Moderate

Concomitant use increases risk of gastrointestinal side effects.

Salicylates + Probenecid🟡Moderate

Salicylates antagonize the uricosuric action of probenecid.

Salicylates + Probenecid And Colchicine🟡Moderate

Salicylates antagonize the uricosuric action of probenecid.

Salicylates + Sodium Chloride, Sodium Lactate, Potassium Chloride, Calcium Chloride And Dextrose Monohydrate🟡Moderate

Renal clearance of acidic drugs like salicylates may be increased due to alkalinizing action of lactate.

Salicylates + Sulfadiazine🟡Moderate

Salicylates may displace sulfonamides from plasma albumin and increase concentrations of free drug in plasma.

Salicylates + Timolol Maleate🟡Moderate

High-dose salicylate therapy may cause acid-base and electrolyte disturbances leading to toxicity when combined with dorzolamide.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.